This organization files Form 990, which has no section for application policy. Its filings cannot say either way.
The latest filing we hold carries no statement about applications. That is not the same as closed: public-charity Form 990s have no field for it, and many foundations leave the section blank.
Grants paid by year
Total assets by year
Where the money went · FY2024
Form 990 splits expenses into program services, management and fundraising. The split is self-reported, and a grantmaker, a research institute and a direct-service nonprofit book the same work differently. A line the return does not carry reads "not available"; it is never counted as zero.
| Year | Form | Revenue | Expenses | Grants paid | Assets | Net assets |
|---|---|---|---|---|---|---|
| FY2024 | 990 | $1,465,263 | $330,368 | $292,000 | $2,077,910 | $2,076,840 |
| FY2023 | 990 | $432,152 | $230,111 | $212,000 | $915,978 | $915,978 |
| FY2022 | 990 | $374,295 | $225,656 | $213,390 | $715,769 | $713,937 |
| FY2021 | 990 | $293,809 | $273,734 | $262,518 | $567,130 | $565,298 |
Figures are as reported on the e-filed return, with no restatement. Fiscal years are the funder's own tax year, labelled by the calendar year the period ends in. A blank line means the return does not carry that figure; a real zero shows as $0. When an amended return replaces an original, every figure here uses the amended return. The original is not shown. Giving is what the funder actually paid out toward its charitable purpose in the year (qualifying distributions on Form 990-PF, charitable disbursements otherwise). Assets are what it holds; giving is what moves.
Recipient focus areas
Where recipients are
Based on the 60% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| McGill University | Metabolic Reprograming in Leiomyosarcoma and Gem/tax therapy resistance and response in Leiomyosarcoma. | $150,000 | 2021 | |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| Sharon Anderson | President | 10 | $0 |
| Denice Brice | Secretary | 2 | $0 |
| Howard Smith | Dir | 0 | $0 |
| Edward Kurtz | Treasurer and V. President |
From the officer list on the latest e-filed return. Compensation is as reported there; a blank means the return carries no figure.
| Research project "Multi Omic profiles and invasive properties of extracellular vesicles in Leiomyosarcoma" |
| $150,000 |
| 2024 |
| Mcgill University | METABOLIC REPROGRAMING IN LEIOMYOSARCOMA (a multi year study) | $150,000 | 2023 |
| Memorial Sloan KitteringNew York City, NY | $100,000 awarded to Dr. Sujana Movva (Sloan Kettering) for her study, "Identifying Biomarkers Predictive of Benefit to Rucaparib and Nivolumab in Patients with Advanced Leiomyosarcoma." This study will analyze who responds the PARP inhibitor, Rucaparib. and $12518 for Identification of a Novel Treatment Strategy for Uterine Leiomyosarcoma in Genotype Defined Patient Population. | $112,518 | 2021 |
| Ichon School of MedicineNew York, NY | Build an integrated multi-omic + functional validation platform using patient-derived ULMS models to identify and validate therapeutic targets, then generalize findings using public ULMS datasets. | $67,000 | 2024 |
| Cedars SinaiLos Angeles, CA | Cancer research. | $50,000 | 2022 |
| City of HopeDUARTE, CA | Extension of grant made in 2022. Development of an Immune Biomarker for Metastatic Disease in Retroperitoneal Leiomyosarcoma (RP LMS). | $50,000 | 2024 |
| Sarcoma Alliance for Research CollaborationAnn Arbor, MI | Cancer research | $50,000 | 2022 |
| City of HopeDuarte, CA | Ongoing LMS research conducted by Dr. William Tseng. | $50,000 | 2022 |
| Ichan School of MedicineNew York, NY | Leiomyosarcoma Cancer Research | $50,000 | 2023 |
| Dana Farber Cancer InstituteBoston, MA | Cancer research | $38,635 | 2022 |
| Stanford UniversityStanford, CA | Research regarding "Distribution of Novel Human Macrophage Subsets in LMS" | $25,000 | 2024 |
| Tatiana OmelchenkoNew York, NY | Cancer research. | $19,138 | 2022 |
| SARCAnn Arbor, MI | Sponsorship supports investigator travel, follow up meetings for present and future Researchers. SARC is a 501C3 organization. | $10,000 | 2023 |
| The Rockefeller UniversityNew York, NY | Cancer research. | $5,618 | 2022 |
| 2 |
| $0 |
Nearest by size, location and giving pattern in the database. Geography weighs heavily. Treat it as a starting list, not a ranking of fit.
Form 990 · FY2023 · period ending Dec 31, 2023IRS bulk XML
Filing id 202443209349317749
Form 990 · FY2022 · period ending Dec 31, 2022
Filing id 202303119349302860
Form 990 · FY2021 · period ending Dec 31, 2021
Filing id 202233189349317968
Form 990 · FY2017 · period ending Dec 31, 2017
Filing id 201803199349319255
Form 990 · FY2016 · period ending Dec 31, 2016
Filing id 201733179349307563
IRS filings are the source for every fact on this page. Nothing a model writes is ever a source; it can only point at a row here.